▷ In-vitro tests / Carragelose: also effective against SARS-CoV-2 variants

[*]

10.06.2021 – 16:43

Hermes Arzneimittel GmbH

Pullach i. Isartal (ots)

Recently carried out in-vitro tests show that the active ingredient carragelose, which is obtained from red algae and contained in the nasal spray algovir, can inactivate the alpha, beta and gamma variants of the SARS-CoV-2 virus [1]. Even with the increasing prevalence of these virus mutants, algovir remains an effective option for minimizing the risk of Covid-19 infection in addition to general hygiene measures – also for pregnant women, breastfeeding women and children from one year old.

The Carragelose contained in the cold spray algovir is a natural active ingredient from red algae with a broad spectrum of action against a large number of viruses that cause respiratory diseases such as flu. Carragelose forms a protective film on the nasal lining and prevents the viruses from attaching to the cells in the lining. This reduces their multiplication and spread in the body. A number of previous laboratory studies with cell cultures [2,3,4,5] and a clinical study [6,7] were able to show that Carragelose also inactivates the SARS-CoV-2 virus in the wild-type variant.

New in vitro tests now confirm that this also applies to the alpha (B.1.1.7), beta (B.1.351) and gamma (P.1 *) mutants with similar effectiveness [1]. This is relevant insofar as the virus variants now clearly determine what happens in the pandemic. According to the Robert Koch Institute, the alpha variant first discovered in Great Britain has long dominated in Germany. Their share in samples tested for SARS-CoV-2 was already almost 92 percent at the beginning of May [8]. The carragelose-containing nasal spray algovir (from the pharmacy) remains an option that goes beyond general hygiene measures in order to minimize the risk of Covid-19 infection.

See also  Scotch & Soda and Klarna, together with the nonprofit organization Trees For All, are launching an international campaign to support global reforestation

[*] Full Scientific Name of P1 (L18F T20N P26S D138Y R190S K417T E484K N501Y D614G H655Y T1027I)

Literature:

[1] Marinomed AG. Marinomed Biotech AG publishes positive data on the effectiveness of Carragelose against SARS-CoV-2 mutations.

https://ots.de/3UZHfi, last accessed on April 28, 2021.

[2] Kumbhar, Popat S.; Pandya, Anjali K.; Manjappa, Arehalli S.; Disouza, John I.; Patravale, Vandana B. Carbohydrates-based diagnosis, prophylaxis and treatment of infectious diseases: Special emphasis on COVID-19. Carbohydrate Polymer Technologies and Applications ; 2:100052, 2021. https://www.sciencedirect.com/science/article/pii/S2590049821000102.

[3] Jiang X, Li Z, Young DJ, Liu M, Wu C, Wu YL, Loh XJ. Toward the prevention of coronavirus infection: what role can polymers play? Mater Today Adv. 2021 Jun;10:100140. doi: 10.1016/j.mtadv.2021.100140.

[4] Bansal S, Jonsson CB, Taylor SL et al. Iota-carrageenan and Xylitol inhibit SARS-CoV-2 in cell culture. bioRxiv preprint 2020, doi: DOI 10.1101/2020.08.19.225854.

[5] Morokutti-Kurz M, Fröba M, Graf P, Große M, Grassauer A, et al. Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro. PLOS ONE 2021;16(2):e0237480. DOI 10.1371/journal.pone.0237480.

[6] ICT MILSTEIN, CONICET- Pablo Cassará Foundation. The efficacy of nasal spray with carrageenan for the prevention of COVID-19 has yielded positive results – CARR Preliminary Report, 02/18/2021. Buenos Aires, Argentinien: ICT MILSTEIN. Abgerufen am: 10.06.2021. https://ots.de/xHUUl5.

[7] NIH ClinicalTrials.gov. Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19 Disease (CARR-COV-02), ClinicalTrials.gov Identifier: NCT04521322. Letzter Zugriff: 10.06.2021. ClinicalTrials.gov – NCT04521322.

[8] https://ots.de/1vb6CS

Press contact:

Press contact
Dr. Andreas Erber
HERMES ARZNEIMITTEL GMBH
Georg-Kalb-Strasse 5 – 8
82049 Pullach i. Isartal
Tel. +49 (0)89-79 102-138
Fax +49 (0)89-79 102-139
Email: [email protected]
www.hermes-arzneimittel.com

See also  New strategy against pancreatic cancer

Original content from: Hermes Arzneimittel GmbH, transmitted by news aktuell

.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.